Biocept Inc
OTC:BIOCQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BIOCQ's latest stock split occurred on May 17, 2023
The company executed a 1-for-30 stock split, meaning that for every 30 shares held, investors received 1 new share.
Before the split, BIOCQ traded at 0.2103 per share. Afterward, the share price was about 5.39.
The adjusted shares began trading on May 17, 2023. This was BIOCQ's 4th stock split, following the previous one in Sep 8, 2020.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 27, 2026
|
M
|
Mitsubishi Logisnext Co Ltd
TSE:7105
|
1-for-22962728
/22962728
|
1529 999999.9999 JPY | N/A |
|
Apr 27, 2026
|
|
Intsig Information Co Ltd
SSE:688615
|
1-for-1
x1
|
180.14 127.0214 CNY | 128 128 CNY |
|
Apr 27, 2026
|
|
Nousouken Corp
TSE:3541
|
1-for-550000
/550000
|
763 763 JPY | N/A |
|
Apr 27, 2026
|
F
|
Friendly Corp
TSE:8209
|
1-for-1355800
/1355800
|
312 999999.9999 JPY | N/A |
|
Apr 27, 2026
|
I
|
IA Inc
KOSDAQ:038880
|
1-for-10
/10
|
135 1350 KRW | 1231 1231 KRW |
688615
3541
Biocept Inc
Glance View
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. The company provides blood-based liquid biopsy technology.
